Latest stories on KZIA
Kazia Therapeutics announces first patient dosed in PNOC035 study
The Fly56 · neutralproduct/pr
BTIG raises Kazia Therapeutics stock price target on trial data
Investing.com Analyst Ratings63 · neutralanalyst
Kazia Therapeutics price target raised to $40 from $34 at BTIG
The Fly67 · bullishanalyst
Kazia Therapeutics announces new preclinical, translational data on paxalisib
The Fly59 · neutralproduct/pr
Kazia Therapeutics expands paxalisib trial into HR+/HER2- breast cancer
The Fly63 · neutralproduct/pr
Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering
PR Newswire28 · bearishgeneral
Kazia Therapeutics: Worth Speculating On Paxalisib's TNBC Data
Seeking Alpha63 · neutralproduct/pr
Kazia Therapeutics Unveils New Investor-Focused Website
TipRanks55 · neutralgeneral
Kazia Therapeutics stock falls on $40M public offering
Investing.com Markets28 · bearishgeneral
Kazia Therapeutics 2.58M share Spot Secondary priced at $15.50
The Fly24 · bearishgeneral
Kazia Therapeutics announces pricing of $120M public offering
The Fly28 · bearishgeneral
Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering
PR Newswire24 · bearishgeneral
Kazia Therapeutics Cuts ATM Offering Capacity to $80 Million
TipRanks28 · bearishgeneral
Kazia Therapeutics announces proposed public offering
Seeking Alpha24 · bearishgeneral
Kazia Therapeutics announces offering of ADS, warrants
The Fly24 · bearishgeneral
Kazia Therapeutics reports 100% clinical benefit rate in breast cancer treatment
The Fly73 · bullishproduct/pr
Kazia Therapeutics Limited Announces Proposed Public Offering
PR Newswire24 · bearishgeneral
Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer
StockTitan73 · bullishproduct/pr
Kazia Therapeutics: Upcoming Data May Validate Best-In-Class Potential Of Paxalisib
Seeking Alpha63 · neutralproduct/pr